Status:
RECRUITING
The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Pancreas Adenocarcinoma
MicroRNA
Eligibility:
All Genders
20+ years
Brief Summary
Previous research has shown that microRNAs in the blood can serve as biomarkers for early pancreatic cancer, with potential applications including detection, differential diagnosis, and prognosis pred...
Eligibility Criteria
Inclusion
- Pancreatic ductal adenocarcinoma
- Proven by pathology
- Patients who have not received anti-cancer therapies
Exclusion
- Less than 20 years old
- Unable to provide inform and consent
- Patients who have active malignancy other than pancreatic adenocarcinoma
- Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing
- Life expectancy less than 3 months
Key Trial Info
Start Date :
July 6 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06497777
Start Date
July 6 2024
End Date
June 1 2026
Last Update
July 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100225